RxDoctor Payments Data

Patrick Gagnon

Psychiatric/Mental Health · Milford, CTNPI 1083748214

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 630 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 24.3% of the total. Reporting peaked in 2023 at $4,073 and has fallen 73.3% since, to $1,087 in 2025. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,060in general payments, 2019–2025

Across 630 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Lundbeck LLC$1K
  • Teva Pharmaceuticals USA, Inc.$886
  • Axsome Therapeutics, Inc.$846
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$15,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,060 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl24$36,142
CaplytaLumateperone Tosylate16$26,382
RexultiBrexpiprazole13$19,130
Sertraline Hcl17$1,326
Alprazolam78$1,045
Duloxetine Hcl44$791
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$615
Mirtazapine24$520
Clonazepam49$494
Gabapentin12$452
Bupropion XlBupropion Hcl12$406
Oxcarbazepine14$271
Trazodone Hcl31$258
Quetiapine Fumarate18$226
Venlafaxine Hcl14$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$3,664$36,14224 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$2,166$26,38216 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,583$19,13013 claims
Almatica Pharma LLCSertraline Hcl$19$1,32617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →